NATCO Pharma Limited is significantly increasing its investment in eGenesis, Inc., a biotechnology company focused on developing transplantable organs using genome engineering. The company announced an additional US$14 million investment, bringing its total stake to US$22 million. This strategic move aims to advance eGenesis’s groundbreaking technology for addressing global organ shortages and transforming organ failure treatments, particularly in kidney, liver, and heart transplants.
NATCO Pharma Expands Investment in eGenesis
NATCO Pharma Limited has announced a substantial expansion of its investment in eGenesis, Inc., a pioneering biotechnology firm. The company is injecting an additional US$14 million into eGenesis, raising NATCO’s total investment to US$22 million. This latest funding is channeled through NATCO Pharma (Canada) Inc. (US$9.5 million) and NATCO Pharma South Africa Proprietary Limited (US$4.5 million) via convertible promissory notes. This follows an earlier investment of US$8 million in preferred stock made by NATCO Pharma Limited in 2024.
Advancing Organ Transplant Technology
eGenesis, Inc. is at the forefront of developing safe and effective transplantable organs through a genome engineering-based approach. Its unique EGEN™ Platform addresses molecular incompatibilities and viral risks using genetic engineering, aiming to alleviate the critical global organ shortage. The company is advancing development programs for kidney transplants, acute liver failure, and heart transplants. Notably, eGenesis announced the world’s first porcine kidney transplant in a living patient in March 2024, authorized by the U.S. FDA, with subsequent successful transplants in two additional patients.
Strategic Rationale
The investment underscores NATCO Pharma’s strategic focus on innovative therapeutic programs that address critical unmet medical needs. eGenesis’s work in creating a sustainable supply of transplantable organs represents a significant advancement in regenerative medicine and a potential solution to the persistent organ donor deficit. The collaboration leverages eGenesis’s advanced gene editing capabilities with NATCO’s pharmaceutical expertise.
eGenesis Overview
eGenesis, Inc., incorporated on October 1, 2015, is a clinical stage company based in Cambridge, Massachusetts, USA. It utilizes multiplex gene editing and genome engineering to develop transplantable organs and therapeutic cells. While currently in clinical trials, eGenesis is considered pre-revenue, with its presence primarily in the United States of America.
Source: BSE
